TiGenix Presents Positive Results of Potential Crohn’s Therapy, Announces Phase 3 Study

TiGenix Presents Positive Results of Potential Crohn’s Therapy, Announces Phase 3 Study
TiGenix will present positive results of Cx601 to treat complex perianal fistulas in Crohn's disease patients at the upcoming World Congress of Gastroenterology ACG 2017 meeting in Orlando, Florida. The company will discuss results from its 52-week ADMIRE-CD Phase 3 trial (NCT01541579) and present the upcoming ADMIRE-CD-II (NCT03279081) — a global Phase 3 clinical trial designed to support a future biologic license application to the U.S. Food and Drug Administration (FDA). The presentation, “One-year Efficacy and Safety of a Single Dose of Cx601, Allogeneic Expanded Adipose-Derived Mesenchymal Stem Cells, for Complex Perianal Fistulas in Crohn's Disease: Long-Term Results of a Phase 3, Randomized, Double-Blind Clinical Trial” will take place Oct. 18 at 10 a.m. TiGenix, based in Belgium, exploits the anti-inflammatory properties of allogeneic, or donor-derived, stem cells to develop therapies for serious medical conditions. Its lead product to treat Crohn's patients with complex perianal fistulas is Cx601, a local administration of allogeneic expanded adipose-derived stem cells (eASCs). Last year, The Lancet published 24-week data of ADMIRE-CD under the title “Expanded allogenei
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *